Abstract
The selective serotonin reuptake inhibitors (SSRI) are considered drugs of first choice for the treatment of panic disorder (PD) due to their clinical efficacy demonstrated by 11 randomized placebo-controlled trials and favorable side effects profile. SSRI’s mechanism of action in PD treatment still not completely understood, but the role of serotonin in the pathophysiology of this disorder has been studied for the last few years by neuroimaging, neurochemical and challenge studies. In this chapter, efficacy studies, common side effects and drug interactions of the SSRI are described as well as general recommendations for their clinical use in PD.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013;28:33–45.
Batelaan NM, Van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol. 2012;15:403–15.
Schmidt NB, Keogh ME. Treatment of panic. Annu Rev Clin Psychol. 2010;6:241–56.
Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007;1:CD004364.
Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry. 2007;7:18.
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1.
Bakker A, van Balkom AJ, Spinhoven P. SSRI vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.
Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215–35.
Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology. 2006;31:1–11.
Kennett GA, Lightowler S, de Biasi V, et al. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology. 1994;33(12):1581–8.
Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T. Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav. 2004;78(4):683–9.
Gorman JM, Kent JM, Sullivan GM, Coplan JM. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493–505.
Lai CH, Wu YT, Yu PL, Yuan W. Improvements in white matter micro-structural integrity of right uncinate fasciculus and left fronto-occipital fasciculus of remitted first-episode medication-naïve panic disorder patients. J Affect Disord. 2013;150(2):330–6.
Lai CH, Wu YT. Changes in gray matter volume of remitted first-episode, drug-naïve, panic disorder patients after 6-week antidepressant therapy. J Psychiatr Res. 2013;47(1):122–7.
Miller HE, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry. 2000;176:182–8.
Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35 % carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol. 1997;17:97–101.
Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002;16:5–14.
Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987;7(5):329–32.
Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1991;10(2):119–21.
Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry. 1998;155:1570–7.
Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001;179:514–8.
Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36–42.
Lecrubier Y, Bakker A, Dunbar G, Judge R; the Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand. 1997; 95: 145–52.
Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007;194:233–42.
Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005;66:34–40.
Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173(7):54–60.
Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010–6.
Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189–95.
Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a double blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2003;64:1322–7.
Nair NPV, Bakish D, Saxena B, Amin M, Schwartz G, West TEG. Comparison of fluvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety. 1996;2:192–8.
Asnis GM, Hameedia FA, Goddardb AW, Potkin SG, Black D, Jameel M, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001;103:1–14.
Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004;65:405–13.
Lepola U, Arato M, Zhu Y, Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003;64:654–62.
Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15:171–80.
Cavaljuga S, Licanin I, Kapic E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn J Basic Med Sci. 2003;3:27–31.
Ribeiro L, Busnello JV, Kauer-Sant’Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34:1303–7.
Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34:85–90.
Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001;21:335–9.
Baldwin DS, Birtwistle J. The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry. 1998;59 Suppl 8:39–44. discussion 45–6.
Topiwala A, Chouliaras L, Ebmeier KP. Prescribing selective serotonin reuptake inhibitors in older age. Maturitas. 2014;77(2):118–23.
Kostev K, Rex J, Eith T, Heilmaier C. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. Ger Med Sci. 2014;12:Doc15.
Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792–804.
Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(10):1365–71.
Kimmel RJ, Seibert J. Is antidepressant-associated mania always an evidence of a bipolar spectrum disorder? A case report and review of the literature. Gen Hosp Psychiatry. 2013;35(5):577.
Mendhekar DN, Gupta D, Girotra V. Sertraline-induced hypomania: a genuine side-effect. Acta Psychiatr Scand. 2003;108(1):70–4.
Akiskal HS, Hantouche EG, Allilaire JF, Sechter D, Bourgeois ML, Azorin JM, et al. Validating antidepressant-associated hypo- mania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord. 2003;73(1–2):65–74.
Gordon M, Melvin G. Selective serotonin re-uptake inhibitors—a review of the side effects in adolescents. Aust Fam Physician. 2013;42(9):620–3.
Mahendran R. The risk of suicidality with selective serotonin reuptake inhibitors. Ann Acad Med Singapore. 2006;35(2):96–9.
Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291–7.
Chemali Z, Chahine LM, Fricchione G. The use of selective serotonin reuptake inhibitors in elderly patients. Harv Rev Psychiatry. 2009;17(4):242–53.
Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86(4):203–15.
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67.
Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206–27.
Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011;12(6):570–7.
Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010;50(2):264–72.
Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007;47(2):266–9.
Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE, Evans RW, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089–99.
Harvard Medical School. Antidepressants and tamoxifen. Drug interactions may increase risk of cancer recurrence or death. Harv Ment Health Lett. 2010;26(12):6–7.
Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.
Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas. 2010;67(4):296–308.
Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340(8):c693.
Carvalho AF, Hyphantis T, Sales PM, Soeiro-de-Souza MG, Macêdo DS, Cha DS, et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev. 2014;40(3):349–55.
Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(Suppl):2477–97.
Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113–6.
Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811–9.
Löppönen P, Tetri S, Juvela S, Huhtakangas J, Saloheimo P, Bode MK, et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. J Neurosurg. 2014;120(6):1358–63.
Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049–51.
Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients—influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18(5):412–6.
Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433–8.
Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–65.
American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2009.
Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11–5. discussion 16.
Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17(5):217–25.
Andrews G. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry. 2003;37:641–56.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety,Obsessive-Compulsive and Post-Traumatic Stress Disoders, et al. World Federation of Societies of Biological psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry. 2008;9:248–312.
Canadian Psychiatric Association (CPA). Clinical practice guidelines management of anxiety disorders. Can J Psychiatry. 2006;51(Suppl):9–91.
Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120–6.
Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry. 1991;52(Suppl):18–23. discussion 24–5.
Wright J, Clum GA, Roodman A, Febbraro GA. A bibliotherapy approach to relapse prevention in individuals with panic attacks. J Anxiety Disord. 2000;14:483–99.
Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry. 1996;53:689–94.
Nash MS, Willets JM, Billups B, John Challiss RA, Nahorski SR. Synaptic activity augments muscarinic acetylcholine receptor-stimulated inositol 1,4,5-trisphosphate production to facilitate Ca2+ release in hippocampal neurons. J Biol Chem. 2004;279(47):49036–44.
Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863–7.
Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26(8):537–42.
Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61–74.
Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465–73.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mochcovitch, M.D., Baczynski, T.P. (2016). Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors. In: Nardi, A., Freire, R. (eds) Panic Disorder. Springer, Cham. https://doi.org/10.1007/978-3-319-12538-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-12538-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12537-4
Online ISBN: 978-3-319-12538-1
eBook Packages: MedicineMedicine (R0)